ZYNERBA PHARMACEUTICALS INC stock forecast: up to 0.81 USD ZYNE stock price prognosis
Forecast for Tue 29 Nov 2022 price
ZYNERBA PHARMACEUTICALS INC stock price forecast for further price development up to 3.98% (time horizon: 1 day) and price target of 0.81 USD. Negative news sentiment. Short-term (time horizon: 2 weeks) ZYNERBA PHARMACEUTICALS INC share price prediction for 2022-11-29 with daily closed price projections
News <--> Close correlation for next day influence (0.03)
Earnings per share
On our site we made daily predictions for finance products based on statistical analysis. You can export / download forecasted data as CSV file, no login required. The information can be used for day trading.
The forecast (dashed curve) of the share price performance is based on historical data.
Our forecast model is based on mathematical, statistical methods.
The website offers price forecasts and analysis tools for equities and other securities,
which are exclusively based on the prices of these securities in the past.
Information about these prices is provided to us by third parties. Although we believe,
If we believe that our sources are reliable, we cannot guarantee the accuracy, completeness, timeliness and
correct sequencing of this information.
We do not investigate the issuers of the securities to which our forecasts relate, nor do we consider
any financial data or other data of such issuers with the exception of the past prices of the securities.
Therefore, our forecasts do not constitute an analysis of other commercial or financial factors or
that may be relevant for future security price flows. Investments require additional considerations.
Our forecasts cannot reflect the specific situation. Experience and risk profile of an individual investor
or the tax implications an investment may have for the investor. Although we believe that
our mathematical models are a tool to try to explore the possibility for future price development
with the help of past performance, such developments are subject to a multitude of different influences.
and therefore not really predictable.
We cannot guarantee the success of any investment you make based on the information published here.
This website is for information purposes only. All information and data on this website cannot be guaranteed
to be accurate,
accuracy, completeness and appropriateness - neither explicit nor implicit.
Summerized Form 10-K with GPT-2
8203;Cannabinoids are a class of compounds derived from Cannabis plants. Clinical data also suggest that cannabidiol has a very high therapeutic index. 8203;Figure 1 — Chemical structure and transdermal gel delivery of cannabidiol. We also collected caregiver-reported data from the CONNECT-FX trial. We expect to discuss a path forward with the FDA in the first half of 2021. There are two primary stages of 22q patient management. These U.S. patents will expire between 2026 through 2038. The FDA has agreed to certain performance goals in the review of NDAs. Most applications for priority review drugs are reviewed in six to eight months. A product cannot be commercially promoted before it is approved. Marijuana and THC are Schedule I controlled substances under the CSA. As a result, increasingly high barriers are being erected to the entry of new products. As of December 31, 2020, we had an accumulated deficit of $202.2 million. In particular, we are studying Zygel in patients with FXS, DEE, ASD and 22q. Claims could also be asserted under state consumer protection acts.
Candlestick patterns can be used as additional information for price prediction. Following list show which pattern applies on latest price information.
Meta analyst score 26.04/100
Good financial position.
Historical view, profit is not growing.
Company revenue is not growing faster compared with the
Institutional ownership list is based on filling form information
Bollinger Bollinger Bands for ZYNERBA PHARMACEUTICALS INC can provide the information where the market is moving based on price information.
ZYNERBA PHARMACEUTICALS INC Short Volume Ratio is shown in the diagram. Short volume sales can be seen as an investor sentiment.
On-Balance Volume information for ZYNERBA PHARMACEUTICALS INC. On-Balance Volume information can be an indicator for bullish or bearish outcome.
Accumulation / Distribution (A/D) indicator information for ZYNERBA PHARMACEUTICALS INC. The indicator identify divergences between price and volume flow.
Aroon Oscillator information for ZYNERBA PHARMACEUTICALS INC. The trend-following indicator can show the strengh of a current trend and likelihood that trend can continue.
Average Directional Index (ADX) information for ZYNERBA PHARMACEUTICALS INC. The index can be used to identify the strengh of a trend.
Moving Average Convergence Divergence (MACD) for ZYNERBA PHARMACEUTICALS INC. The indicator helps to predict trend direction and the momentum of the trend.
Stochastic Oscillator as momentum indicator for ZYNERBA PHARMACEUTICALS INC. The indicator is useful for identifying overbought and oversold levels.
Relative Strength Index (RSI) for ZYNERBA PHARMACEUTICALS INC. RSI is a momentum oscillator that measures the speed and change of price development.
The momentum indicator was created by analyst Welles Wilder. The result compares recent gains and losses over restricted time period.
Primary usage of the indicator is to identify overbought or oversold signals.
When RSI indicator reaches a value of 70 it could mean that speculators should consider selling, suggests Wilder and Chong. Or vice versa when selling excess at which the RSI Indicators show a value of 30
Relative Strength Index for Developing Effective Trading Strategies in Constructing Optimal Portfolio